Contribution of prostaglandin E1 treatment in patients with critical limb ischemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065356" target="_blank" >RIV/00159816:_____/16:00065356 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00090353 RIV/62157124:16370/16:43874497

Result on the web

<a href="http://www.ijcem.com/files/ijcem0014940.pdf" target="_blank" >http://www.ijcem.com/files/ijcem0014940.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Contribution of prostaglandin E1 treatment in patients with critical limb ischemia

Original language description

Background and aims: Peripheral arterial disease (PAD) in advanced stages has severe disabling complications. Major amputations (MA) and high mortality rates are common in patients with critical limb ischemia (CLI). Revascularization (interventional angioplasty or vascular surgery) appears to be possible in the large majority of cases if these patients are referred to a specialist earlier. Patients with CLI and lacking options for revascularization have worse prognosis. The purpose of this retrospective study was to investigate the impact of including prostaglandins in the treatment of patients with CLI lacking the possibility of revascularization. Method: This retrospective study cohort includes 67 patients (34 male and 33 female), mean age 71 +/- 10.7 years treated for CLI not suitable for revascularization. Prostaglandin E1 (alprostadil) was applied by intravenous perfusion with doses of 40 mu g twice a day for 2 weeks. Results: 23 patients (34.3%) underwent amputation and 17 patients (40.3%) died during the total follow-up period (01/2009-07/2014). Mortality rate was higher in patients who have undergone an amputation, in diabetics and in patients without statin medication. Conclusion: Patients with CLI lacking options for revascularization have despite treatment with prostanoids (alprostadil) a poor prognosis, with high amputation rate and increased mortality. Statin medication was a protective factor for survival.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FP - Other medical fields

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

International Journal of Clinical and Experimental Medicine

ISSN

1940-5901

e-ISSN

—

Volume of the periodical

9

Issue of the periodical within the volume

2

Country of publishing house

US - UNITED STATES

Number of pages

5

Pages from-to

3227-3231

UT code for WoS article

000374655200314

EID of the result in the Scopus database

—